Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
Stock Information for Citius Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.